drugset / Trial / NCT05992597
ZR2 Sequential Immunochemotherapy for Newly Treated MCL
NaSingle-groupOpen-labelTreatment
Summary
Patients with newly diagnosed MCL were treated with ZR2 regimen for 3 cycles, followed by 3 cycles of immunochemotherapy, and zebrutinib maintenance therapy for 2 years after the end of induction therapy, in order to improve the remission rate and prognosis of patients with induction therapy.
Timeline
- Start
- 2022-08-01
- Primary completion
- 2025-08-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 2 g | — |
| Subject | Dexamethasone | Small molecule | 40 mg | — |
| Subject | Lenalidomide | Other / unclassified | 24 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Zebutinib | Unknown | 160 mg | — |